Wave Life Sciences Ltd
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $465.22 million
- Book Value:
- Revenue TTM:
- $36.56 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Wave Life Sciences Ltd had its IPO on 2015-11-11 under the ticker symbol WVE.
The company operates in the Healthcare sector and Biotechnology industry. Wave Life Sciences Ltd has a staff strength of 250 employees.
Shares of Wave Life Sciences Ltd opened at $4.7 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.67 - $5.14, and closed at $5.09.
This is a +8.3% increase from the previous day's closing price.
A total volume of 324,963 shares were traded at the close of the day’s session.
In the last one week, shares of Wave Life Sciences Ltd have increased by +12.11%.
Wave Life Sciences Ltd's Key Ratios
Wave Life Sciences Ltd has a market cap of $465.22 million, indicating a price to book ratio of 10.2118 and a price to sales ratio of 111.161.
In the last 12-months Wave Life Sciences Ltd’s revenue was $36.56 million with a gross profit of $-73644000 and an EBITDA of $-130349000. The EBITDA ratio measures Wave Life Sciences Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Wave Life Sciences Ltd’s operating margin was -372.6% while its return on assets stood at -38.41% with a return of equity of -10258.19%.
In Q2, Wave Life Sciences Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 5794.9%.
Wave Life Sciences Ltd’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.36 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Wave Life Sciences Ltd’s profitability.
Wave Life Sciences Ltd stock is trading at a EV to sales ratio of 105.3397 and a EV to EBITDA ratio of -3.0308. Its price to sales ratio in the trailing 12-months stood at 111.161.
Wave Life Sciences Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $229.99 million
- Total Liabilities
- $140.23 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Wave Life Sciences Ltd ended 2023 with $229.99 million in total assets and $0 in total liabilities. Its intangible assets were valued at $229.99 million while shareholder equity stood at $-51720000.00.
Wave Life Sciences Ltd ended 2023 with $0 in deferred long-term liabilities, $140.23 million in other current liabilities, 839675000.00 in common stock, $-1015846000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $172.97 million and cash and short-term investments were $172.97 million. The company’s total short-term debt was $6,285,000 while long-term debt stood at $0.
Wave Life Sciences Ltd’s total current assets stands at $184.71 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $12.38 million and inventory worth $0.
In 2023, Wave Life Sciences Ltd's operating cash flow was $-72000.00 while its capital expenditure stood at $72000.
Comparatively, Wave Life Sciences Ltd paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Wave Life Sciences Ltd stock is currently trading at $5.09 per share. It touched a 52-week high of $7.12 and a 52-week low of $7.12. Analysts tracking the stock have a 12-month average target price of $7.69.
Its 50-day moving average was $4.36 and 200-day moving average was $4.42 The short ratio stood at 15.58 indicating a short percent outstanding of 0%.
Around 2121.9% of the company’s stock are held by insiders while 7167.8% are held by institutions.
Frequently Asked Questions About Wave Life Sciences Ltd
Similar Industry Stocks (Biotechnology)
Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington’s disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer’s and Parkinson’s diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.